Introduction: Increasing evidence has demonstrated that exon 19 deletions (Del19) and L858R mutation in EGFR have different prognostic and predictive roles in NSCLC. We aimed to investigate whether these two mutations produced differences in mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Methods: Consecutive patients with advanced EGFR-mutant NSCLC who acquired resistance to EGFR tyrosine kinase inhibitors and underwent postprogression biopsy were enrolled. Mechanisms including T790M mutation, mesenchymalepithelial transition proto-oncogene (MET) amplification, and histological transformation, as well as KRAS, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation, and anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion, were analyzed.
Results: The prevalence of T790M mutation was significantly higher in the Del19 subgroup than that in L858R subgroup (50.4% versus 36.5%, p ¼ 0.043). Apart from this, there was no difference in other mechanisms including MET amplification and histological transformation. The median overall survival (OS) of patients with T790M mutation was 36.0 months (95% confidence interval [CI] : 30.9-41.2), which was significantly longer than the 26.5 months (95% CI: 24.0-29.0) in MET-positive patients, 19.7 months (95% CI: 18.2-21.2) in patients with histological transformation, and 23.0 months (95% CI: 17.4-28.6) in the KRAS/PIK3CA/ALK-altered population (p ¼ 0.021). The hazard ratios of the MET-amplification subgroup and subgroup with histological transformation were 1.809-fold and 2.370-fold higher than that in T790M-positive subgroup. The median OS times were months 33.3 (95% CI: 28.9-37.7) in the Del19 subgroup and 26.4 months (95% CI:
Introduction
Exon 19 deletions (Del19) and the exon 21 mutation L858R are both common EGFR mutations, and patients with these mutations are recommended for first-line EGFR tyrosine kinase inhibitor (TKI) therapy.
However, recent studies have shown that such patients have different survival outcomes in response to both EGFR TKIs and chemotherapy. [1] [2] [3] EGFR TKI treatment was demonstrated to be more effective in patients with Del19 than in those with L858R mutation. [1] [2] [3] In contrast, patients randomly assigned to chemotherapy who had an exon 21 L858R substitution had statistically significantly longer progression-free survival than those with Del19, according to the meta-analysis conducted by Lee et al. 3 As previously reported by Shigematsu et al., 4 patients with the L858R mutation had relatively prolonged survival compared with those with Del19 in the absence of EGFR TKI therapy. These findings suggest that the difference in prognosis between EGFR Del19 and L858R disease might be related to efficacy of the EGFR TKIs. TKI therapy might change the natural history of patients harboring an EGFR mutation, converting Del19 lung cancer from a disease with a poor prognosis to one with a more favorable prognosis. 5 Although mechanisms of acquired resistance to EGFR TKIs have been well identified in previous studies, few have assessed whether there was a discrepancy in EGFR TKI resistance mechanisms between Del19 and L858R mutations. Our purpose was to investigate whether these two mutations produced differences in mechanisms of resistance to EGFR TKIs and had an impact on survival.
Patients and Methods

Study Design
Consecutive patients with advanced EGFR-mutant lung cancer who acquired resistance to first-or secondgeneration EGFR TKIs and underwent postprogression biopsies at Guangdong Lung Cancer Institute (Guangzhou, People's Republic of China) between January 2010 and July 2014 were enrolled. Eligibility was based on Jackman's clinical definition of acquired resistance to EGFR TKIs. 6 The exclusion criteria were (1) a de novo T790M mutation and (2) an uncommon EGFR mutation (mutation other than Del19 or L858R). Clinical data were obtained from the electronic medical record database of Guangdong Lung Cancer Institute. All patients provided written informed consent for use of their tumor samples. The protocol was approved by the Research Ethics Committee of Guangdong General Hospital (no. GDREC2013185h(R2)).
We conducted a systematic review of the scientific literature published up to January 1, 2017, using PubMed to identify studies involving mechanisms of acquired resistance to EGFR TKIs. Data regarding the numbers and percentages of Del19 and L858R mutation subgroups were collected.
Analysis of Resistance Mechanisms
The postprogression biopsy samples were assessed for the T790M mutation, mesenchymal-epithelial transition proto-oncogene (MET) amplification, histological transformation, and anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion, as well as for mutations in KRAS and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA). All tissues were histologically assessed by two independent pathologists. Thyroid transcription factor 1 and p40 immunohistochemistry was performed on samples that were suggestive of a transformation of squamous cell carcinoma by using hematoxylin and eosin staining. Neuroendocrine immunohistochemistry for synaptophysin, chromogranin, and CD56 was performed on samples that were suggestive of SCLC transformation. Mutations in exons 18 to 21 for EGFR and codons 12, 13, 59, and 60 for KRAS were detected by polymerase chain reaction (PCR)-based sequencing.
7 PIK3CA mutations in exons 9 and 20 were detected by high-resolution DNA melting analysis. 8 Variations of echinoderm microtubule associated protein like 4 gene (EML4)-ALK fusion were analyzed by using multiple PCR and rapid amplification of complementary DNA ends on complementary DNA. 9 MET amplification was determined by using quantitative PCR on DNA, and the cutoff point for high-level MET amplification was defined as the mean plus or minus five SD of the control group. 10 All experimental procedures and conditions were as previously described in the references.
Statistical Analysis
The chi-square test was used to compare qualitative data, and those with an expected frequency less than 5 were analyzed using Fisher's exact test. A nonparametric test was used to analyze the quantitative data. OS was measured as the time from the diagnosis of advanced disease to the date of death from any cause or the last follow-up. The survival outcome was analyzed by the Kaplan-Meier method and compared between different groups using the log-rank test. Multivariate Cox proportional hazards regression was used to evaluate independent predictive factors associated with OS. A two-sided p value less than 0.05 was considered statistically significant. All analyses were performed with Statistical Package for Social Sciences, version 13.0, software (SPSS, Inc., Chicago, IL).
Results
Baseline Patient Characteristics
A total of 224 patients were evaluated for the present study. The patients' ages ranged from 32 to 87 years (median, 57 years). Adenocarcinoma accounted for 92.9% of cancers among the study population. Of the 224 patients, 102 (45.5%) were male and 52 (23.2%) were smokers. There were more patients with EGFR Del19 (n ¼ 139) than with L858R point mutations (n ¼ 85).
The characteristics of the Del19 and L858R subgroups are listed in Table 1 . Comparisons between these two groups showed no significant difference in patient characteristics except for age. The percentage of patients younger than 55 years was significantly higher in the Del19 group than in the L858R group (47.5% versus 31.8% [p ¼ 0.021]). All patients received EGFR TKIs during their treatment course, including 131 who received gefitinib, 85 who received erlotinib, and eight who received afatinib. The distribution of the three types of EGFR TKIs was similar between the Del19 group and L858R group (p ¼ 0.664). The percentages of patients who were treated with frontline EGFR TKIs were also well matched between the groups (p ¼ 0.252).
Mechanisms of Acquired Resistance to EGFR TKIs
The percentages of each of the resistance mechanisms detected in our study are shown in Figure 1 . Among the 224 patients with advanced EGFR-mutant lung cancer who acquired resistance to EGFR TKIs, the prevalence of the concomitant T790M mutation in their TKI-resistant samples was 45.1% (101 of 224). The prevalence of the T790M mutation was significantly higher in tumors with Del19 than in those with L858R mutations (50.4% versus 36.5% [p ¼ 0.043]). Apart from this, there was no significant difference in the prevalence of other resistance mechanisms between the two groups. The percentage of patients with METpositive disease was 18.7% in the Del19 group versus 20.0% in the L858R group (p ¼ 0.811). The percentage of patients with histological transformation was 5.1% in the Del19 group versus 3.6% in the L858R group (p ¼ 0.746). Additional resistance mechanisms, including KRAS, PIK3CA mutations, and ALK fusions, were found in 5.8% of the patients with Del19 and in 6.1% of the patients with L858R mutation (p ¼ 0.696). In total, 56 of the 224 patients in our study (25.0%) had no evidence of any resistance mechanism.
We conducted a literature review and identified six studies [11] [12] [13] [14] [15] [16] that had provided both exact numbers and percentages of patients with the T790M mutation in separate Del19 and L858R mutation subgroups. We combined our data with those of the other six studies to further confirm the predilection for the T790M mutation in the Del19 population. There were a total of 792 EGFRmutant patients in the combined overall population. We found that 258 of the 473 patients with Del19 (54.5%) and 119 of the 319 patients with the L858R mutation (37.3%) harbored the T790M mutation in their TKIresistant samples. The difference between the two groups was statistically significant (p < 0.001) (Fig. 2) .
Multivariate logistic regression (with a 1% significance level) identified EGFR mutation subtype (p ¼ 0.032) and smoking status (p ¼ 0.039) to be independent predictive factors for T790M mutation status. The probability of development of a T790M mutation in the Del19 subgroup was 1.928-fold higher than that in L858R subgroup (95% confidence interval [CI]: Del, deletion; TKI, tyrosine kinase inhibitor.
1.057-3.516). The prevalence of the T790M mutation was relatively higher in smoking patients than in nonsmokers (adjusted OR ¼ 2.039, 95% CI: 1.037-4.010). 
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a TKI were 12.3% in the Del19 subgroup and 12.9% in the L858R subgroup (p ¼ 0.876). None of the five patients with ALK fusion had ever received crizotinib or other ALK inhibitors, probably owing to unavailability of these drugs at that time. Treatments were generally balanced between patients with Del19 and those with the L858R mutation ( Table 2) .
Survival outcome data were cut off on January 1, 2017, and a total of 191 deaths occurred. The median OS of patients with T790M resistance mutation was 36.0 months (95% CI: 30.9-41.2), which was significantly longer than that of the other subgroups (p ¼ 0.021) (Fig. 3) . The median OS was 26. (Table 3 ). The adjusted hazard ratios of the MET amplification and histological transformation subgroups were respectively 1.809-fold and 2.370-fold higher than that in T790M-positive subgroup.
The median OS was 33.3 months (95% CI: 28.9-37.7) in patients with EGFR Del19, and 26.4 months (95% CI: 23.2-29.6) in the L858R mutation population. The hazard ratio for univariable analysis was 0.721 (95% CI: 0.538-0.967, p ¼ 0.028). However, in multivariable analysis adjusted for T790M genotype or age, the EGFR mutation subtype was no longer found to be significant. The results indicated that the OS superiority of the Del19 population was probably driven by a higher proportion of younger patients whose tumor acquired resistance through the T790M mutation.
Discussion
This study specifically investigated the distinction of TKI resistance mechanisms among patients with Del19 and L858R mutations. Mechanisms including T790M mutation, MET amplification, histological transformation, PIK3CA mutation, and ALK fusion were identified simultaneously in both the Del19 and L858R mutation subgroups. KRAS mutation was found in 1.4% of Del19 patients, but not in L858R patients, which is probably because of the small sample size. There was no significant difference in the prevalence of mechanisms other than the T790M mutation. Development of the T790M mutation was found to be more likely in patients harboring Del19 than in those with L858R mutants (50.4% versus 36.5%). Several previous studies [11] [12] [13] [14] [15] [16] have described the T790M positivity rate between Del19 and L858R mutations; no significant differences were found, except for those identified by Nosaki et al. 16 and Matsuo et al. 15 A pooled analysis was conducted to confirm the predilection for the T790M mutation in the Del19 population. Moreover, Del 19 was more prevalent than L858R mutation as a background EGFR mutation in AURA extension, 17 AURA 2, 18 and AURA 3 19 which dealt with patients with pretreated with an EGFR TKI and T790M-positive NSCLC (71% versus 25%, 65% versus 32%, and 62% versus 32%).
Patients with the T790M mutation, irrespective of EGFR activating mutation subtypes, had better survival beyond EGFR TKI progression, which suggested that resistance acquired through the T790M mutation might follow a more indolent course than clinical resistance without the mutation. Oxnard et al. 20 and Hata et al.
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reported similar results in a white population and a Japanese population, respectively. Notably, preclinical data have also demonstrated that acquisition of the T790M mutation is associated with more indolent growth than in parental cell lines without T790M mutation in the absence of TKI selection. 21 Our results have validated previous findings and further elucidated the association between T790M-independent mechanisms and the better survival of patients with EGFR Del19.
The possible mechanisms responsible for the difference in prevalence of T790M mutation between Del19 and L858R are still unknown. Intrinsic structural basis and differential drug sensitivity had been described in previous studies. [22] [23] [24] Structurally, these mutations map to the vicinity of the active site cleft of the kinase. Del19 removes three to eight residues from the loop leading into the aC-helix, whereas the L858R mutation lies in the activation loop of the kinase. Zhu et al. 24 mimicked the biological behavior of different mutations in vitro and demonstrated that gefitinib inhibited the phosphorylation of EGFR, Akt, and Erk1/2 to a greater degree in Del19 cells than in L858R cells and produced G1 arrest in more cells with Del19.
There are some limitations to this study. It was a retrospective analysis with an overall 14.7% censored rate. In addition, tumor sampling before TKI administration was not performed in half of all patients. As previously reported, 1% to 6% of patients might have a de novo T790M mutation. [25] [26] [27] Furthermore, in 21.4% of cases, cytotoxic chemotherapy was administered between TKI progression and collection of resistant tumor samples, which might have changed the T790M mutation status of the tumors. 28 In conclusion, patients whose tumor acquired resistance through the T790M mutation had a better survival outcome than those in whom resistance was acquired through other mechanisms. Thus, the predilection for the T790M mutation in the Del19 population might help explain why such patients tend to survive longer than patients with the L858R mutation. HR, hazard ratio; CI, confidence interval; MET, mesenchymal-epithelial transition proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; ALK, ALK receptor tyrosine kinase gene; TKI, tyrosine kinase inhibitor; MET, mesenchymal-epithelial transition.
